rhabdomyolysis glp 1 Frontiers rhabdomyolysis glp 1 Does GLP-1

In a 2025 review, the authors describe this species as occupying an extraordinary niche in the human gut, and a model organism studied for its ability to modulate human health and gut microbiome structure.13 In animal studies, it has slowed the development and progression of diabetes , obesity , and irritable bowel disease .14 In human trials, it has helped participants reduce their BMI and improve their diabetic markers.12 Its effects on obesity and diabetes have been recreated in humans as well

doi: 10.1194/jlr.M044669

Mathieu C, Dandona P, Gillard P et al (2018) Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 Study): 24-week results from a randomized controlled trial

Evaluation of novel GLP1 analogue in the treatment of Alzheimer's disease